Lineage Cell Therapeutics, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Lineage Cell Therapeutics, Inc. (LCTX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-06-30 was $14.84M.
- Lineage Cell Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $14.84M.
- Lineage Cell Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $14.84M derived: sum of 3 quarters · filed 2026-08-06 | $14.84M 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $14.84M derived: sum of 2 quarters · filed 2026-08-06 | $14.84M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $14.84M 10-Q · filed 2026-08-06 | $14.84M 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |